Introductory Speakers
Keynote Speakers
Speakers
Jordan Ardill
Speaker
Jordan Ardill is a community-oriented patient whose path has pushed him towards advocacy. He was diagnosed with a rare form of cancer that metastasized into several sites in his body. Raised by entrepreneurial parents, he learned the value of hard work at an early age. Jordan went on to become an elite athlete who saw firsthand the power of teamwork and leaning on the people around you. After years as a successful salesman and eventually becoming self-employed, an autoimmune disease sidelined him, a shift that taught him how fragile health can be and how important it is to live for today. That resilience served him well when he was later diagnosed with cancer. Now doing well while participating in a clinical trial for recurrent disease, Jordan struggles finding a path back to a “normal” quality of life but feels that advocacy and walking alongside others facing cancer can help bring a sense of purpose back into his life.

John Valliant, PhD
Keynote Speaker
Dr. John Valliant is a Professor Emeritus in the Department of Chemistry and Chemical Biology at McMaster University and an internationally recognized scientist, mentor, entrepreneur and expert in medical isotopes and radiopharmaceuticals. His research focused on developing targeted radiopharmaceuticals for the diagnosis and treatment of diseases, particularly cancer. He is the founder and first CEO of the Centre for Probe Development and Commercialization (CPDC), a national centre of excellence advancing the translation of scientific discoveries into clinical applications, enabling the formation of new biotech companies and driving the growth of Canada’s radiopharmaceutical ecosystem. Dr. Valliant was also the founder and CEO of the targeted alpha therapy company, Fusion Pharmaceuticals, which was acquired by AstraZeneca in 2024 for over $2B USD. Dr. Valliant completed his PhD at McMaster University, followed by postdoctoral training at Harvard and MIT, and has received national recognition for his contributions to interdisciplinary research and innovation.

David Hong, MD
Speaker
Dr. David Hong is the Douglas E Johnson Endowed Professor and Deputy Chair of the Department of Investigational Cancer Therapeutics (Phase 1 Program) at MD Anderson Cancer Center, and Clinical Medical Director of its Clinical Translational Research Center. A key leader in developing one of the world’s largest Phase 1 programs, the unit has enrolled 1,200+ patients annually with 280+ active trials. He has served as PI on nearly 110 studies, published over 400 peer‑reviewed articles (H‑index 76), and helped develop multiple FDA-approved therapies. With expertise in targets like c-Met, NTRK, and KRAS, Dr. Hong has led major national trials including NCI‑MATCH arms and co‑founded OncoResponse and Telperian, having received many awards and recognised widely for his mentorship in early-phase clinical research.

Mitchell Elliott, MD, FRCPC
Speaker
Dr. Mitchell Elliott is a Medical Oncologist and physician‑scientist specializing in breast cancer and precision oncology at Yale School of Medicine. He completed training at the University of Toronto and a Phase 1 drug development fellowship at Princess Margaret Cancer Centre, and is a PhD candidate in translational oncology. His research focuses on circulating tumour DNA (ctDNA) and other liquid biopsy approaches to guide treatment decisions and understand drug resistance, particularly in breast cancer. Dr. Elliott has led and contributed to multiple clinical trials, received competitive national funding, and earned international recognition for his work aimed at advancing precision oncology.

Benjamin Haibe-Kains, PhD
Speaker
Dr. Benjamin Haibe‑Kains is the Executive AI Scientific Director at the University Health Network, Senior Scientist at Princess Margaret Cancer Centre, and Professor at the University of Toronto. Trained in bioinformatics in Belgium with postdoctoral work at Harvard, he leads research in AI‑driven precision oncology, integrating large‑scale chemical, imaging, and genomic data to develop predictive models for drug development and treatment response. He holds the Canada Research Chair in Computational Pharmacogenomics and directs multiple data science and AI initiatives at UHN and Princess Margaret.

Yvette Drew, MBBS, FRCPC, PhD
Speaker
Dr. Yvette Drew is a Medical Oncologist and Associate Professor at BC Cancer and the University of British Columbia, specialising in gynaecological cancers and early-phase clinical trials. She completed oncology training in the UK and earned a Cancer Research UK-funded PhD on PARP inhibitors in ovarian cancer. Since joining BC Cancer in 2021, she has led and contributed to multiple early-phase studies, secured research funding, and currently chairs the CCTG Investigational New Drug Committee, with a focus on advancing novel cancer therapies.

Michael Raphael, MD, FRCPC
Speaker
Dr. Michael Raphael is a GI Medical Oncologist at the Odette Cancer Centre at Sunnybrook HealthSciences Centre, specializing in gastrointestinal cancer. He earned his medical degree at Queen’s University and completed internal medicine and medical oncology training at the University of Toronto. He subsequently completed an advanced cancer health services research fellowship and MSc in Healthcare Quality, Risk and Safety at Queen’s University. His research focuses on population-based cancer care, with emphasis on optimizing cancer care coordination and delivery, addressing disparities in treatment access, and evaluating the real-world toxicity and effectiveness of cancer therapies. His work has already influenced practice guidelines globally, and led to a new quality metric routinely used by Cancer Care Ontario (“time to initiating adjuvant chemotherapy”).

Lindsay Carlsson, RN, MN, PhD
Speaker
Dr. Lindsay Carlsson is a Clinician Scientist with the Oncology Nursing Research Centre of Excellence at the Princess Margaret Cancer Centre (PM). She practiced as an oncology nurse for nearly two decades. Within the Phase 1 Program at PM, she advanced clinical research and innovation through roles as a Clinical Research Coordinator and the program’s first Clinical Nurse Specialist. She led VIRTUOSO, an innovative virtual nurse navigator program that enhances access to cancer genomic testing and clinical trials for advanced cancer patients across Ontario. Her research program focuses on cancer genomics, clinical trials navigation, and equitable access to services across the cancer continuum. Dr. Carlsson is also passionate about advancing genomic literacy amongst Canadian nurses, and co-leads the Canadian Nursing Genomics initiative, helping shape national policy and educational agendas.

Raffaele Colombo, PhD
Speaker
Dr. Raffaele Colombo is Director of Medicinal Chemistry at Zymeworks in Vancouver, with over 15 years of experience in drug conjugates, particularly antibody‑drug conjugates (ADCs). He earned his PhD at the University of Milan and completed postdoctoral training at the University of Pittsburgh (NCI CBC/NExT program). He has held roles at Eli Lilly and MedImmune/AstraZeneca, focusing on payload and linker development for ADCs. Since 2020, he has led medicinal chemistry at Zymeworks, advancing ADC technologies. He was named to the PharmaVoice 100 in 2024 and received the 2025 George R. Pettit Award for his contributions to ADC science.

Lucy Ma, MD, FRCPC
Session Chair
Dr. Lucy Ma is an Assistant Professor of Medicine at the University of Toronto and staff Medical Oncologist in the Division of Medical Oncology at the Princess Margaret Cancer Centre. Dr. Ma received her medical degree from the University of Alberta and completed her Internal Medicine and Medical Oncology specialty training at the University of Toronto. Her clinical practice includes the treatment of patients with gastrointestinal and endocrine cancers. Her research interests include clinical trials and biomarker discovery.

Ana Veneziani, MD
Session Chair
Dr. Ana Veneziani is a Medical Oncologist and clinician-investigator at the Princess Margaret Cancer Centre and an Assistant Professor at the University of Toronto. She specializes in gynecologic cancers, with a focus on ovarian cancer, immunotherapy, and early-phase drug development. Her work is highly collaborative, spanning international and multi-institutional clinical trials and translational research initiatives. She has authored senior publications in leading journals, including Nature Reviews Clinical Oncology and Clinical Cancer Research, and received the Merit Award from the American Society of Clinical Oncology (ASCO). Through her research, leadership roles, and mentorship, Dr. Veneziani is advancing innovative, personalized therapies for patients with gynecologic cancers.

Robert Grant, MD, PhD
Debate Moderator
Dr. Robert Grant is an Assistant Professor of Medicine at the University of Toronto and a staff Medical Oncologist in the Division of Medical Oncology at Princess Margaret Cancer Centre. Dr. Grant's clinical practice includes the treatments of patients with biliary and pancreatic cancer. His research focuses on developing and implementing multimodal models to improve clinical decision-making across the cancer continuum.

Sofia Genta, MD
Session Chair
Dr. Sofia Genta is a staff Medical Oncologist at the Sunnybrook Odette Cancer Centre and an Assistant Professor at the University of Toronto. Originally from Italy, she completed her medical training at the Candiolo Cancer Institute and the Oncology Institute of Southern Switzerland. Driven by a longstanding passion for clinical and translational research, she pursued an international fellowship in the Phase 1 Drug Development Program at the Princess Margaret Cancer Centre and the University of Toronto.
Dr. Genta's clinical practice includes the treatment of skin and head and neck cancers. Her research interests focus on liquid biopsy, mechanisms of treatment resistance, and immune-related adverse events associated with immunotherapy.

Eric Fischer, PhD
Keynote Speaker
Dr. Eric Fischer is the Joseph Deitch Family Chair at Dana‑Farber, Director of the Chemical Biology Program, and Professor at Harvard Medical School. His research focuses on ubiquitin‑mediated protein regulation and the development of targeted protein degradation, a novel therapeutic approach. His work on thalidomide helped define its mechanism and inspired new drug discovery strategies now in clinical trials. Dr. Fischer has received multiple awards, including the Damon Runyon Innovation Award, and is a co‑founder of several biotechnology companies.

Keith Stewart, MB ChB, FRCPC, MBA
Introductory Speaker
Dr. Keith Stewart received his medical degree at Aberdeen University Medical School, trained in internal medicine and hematology in the UK, Canada, and the US, and completed an MBA at the Ivey Business School (Western) in 2002. He has held senior research and clinical leadership roles across in Toronto and at the Mayo Clinic, where he was Director of the Center for Individualized Medicine. An internationally recognized expert in the biology, genomics and treatment multiple myeloma, he has published over 350 papers and led clinical trials of novel therapies from first-in-man to practice-changing studies. He has served on numerous medical, scientific, and advisory boards for private and public institutions, including as a non-executive board member of Genomics England.

Bradly Wouters, PhD, FCAHS
Introductory Speaker
Dr. Bradly Wouters is an internationally recognized cancer researcher and leader. He has served as the Executive Vice President, Science and Research at UHN since 2016, after serving as Interim Director of Research at Princess Margaret Cancer Centre. Since joining UHN in 2008 as Senior Scientist and Director of the Princess Margaret Hypoxia Program, he has also held faculty appointments in Medical Biophysics and Radiation Oncology at the University of Toronto. Previously, he was Professor and Head of Experimental Radiation Oncology at Maastricht University in the Netherlands. He leads UHN’s research enterprise with a focus on advancing excellence in basic, translational, and clinical research.

Philippe Bedard, MD, FRCPC
Introductory Speaker
Dr. Philippe Bedard is a Professor of Medicine at the University of Toronto and a Medical Oncologist at Princess Margaret Cancer Centre, where he co-directs the Phase 1 BRAS Drug Development Program and leads the Cancer Genomics Program. He is a co-contact PI for the NCI-funded North American STAR Consortium and focuses on early-phase clinical trials and genomics-driven cancer therapies. He has received national and international awards for his contributions and holds leadership roles with the Canadian Cancer Trials Group and AACR Project GENIE.

Lillian Siu, MD, FRCPC
Introductory Speaker
Dr. Lillian Siu is a senior Medical Oncologist at Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto. She co-directs the BRAS Phase 1 Drug Development Program and holds the BMO Chair in Precision Genomics. She is also a Co-Scientific Lead for Peter Gilgan Centre for Early Cancer Detection Research to create the world’s leading program for early detection and interception of cancer recurrence. A globally recognised leader in early-phase drug development, her research focuses on Phase I trials, head and neck cancers, and translational work in liquid biopsies, biomarkers, and precision medicine. She's held leadership roles with ASCO and AACR, including AACR President (2025/26), and received numerous international awards for her scientific and mentorship contributions. Dr. Siu has authored nearly 400 publications and serves as Co‑Editor‑in‑Chief of Cancer Research Communications.


